Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,

Slides:



Advertisements
Similar presentations
Retinoic Acid Receptor Alpha and Acute Promyelocytic Leukemia Nidhi Thapar April 1, 2004.
Advertisements

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.
CD8 + T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia by Li Ma, Elisa Simpson,
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
HOXA9 is required for survival in human MLL-rearranged acute leukemias by Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-
Dasatinib suppresses in vitro natural killer cell cytotoxicity
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
TCR-MHC-peptide(s): in vivo veritas
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo by Farideh Miraki-Moud, Essam.
Defects in DBA: more than meets the eye
Next-generation leukemia immunotherapy
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,
Gupta V, Tallman MS, Weisdorf DJ
It's all in the timing by Linda J. Bendall Blood
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment by Francis Mussai, Carmela De Santo, Issa Abu-Dayyeh, Sarah Booth,
Rituximab-induced tumor cell agglutination
Tax fingerprint in adult T-cell leukemia
Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
CMV: when bad viruses turn good
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia by Teresa Padró, Sandra Ruiz, Ralf Bieker, Horst Bürger, Martin Steins,
Functional neutrophils from human ES cells
Engineering regulatory T cells against factor VIII inhibitors
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia by Gerald G. Wulf, Rui-Yu Wang, Ingrid Kuehnle, Douglas Weidner, Frank.
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
Acute promyelocytic leukemia, microgranular variant
CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but.
Pegylated arginase I: a potential therapeutic approach in T-ALL
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate by E.L.
Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.
Anergy: the CLL cell limbo
by Zhihong Zeng, Dos D. Sarbassov, Ismael J. Samudio, Karen W. L
Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia.
Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies by Maria C. Petti,
Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J
by John Anastasi, Rizwan Moinuddin, and Christopher Daugherty
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.
Overcoming “aspirin resistance” in MPN
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia by Andrew Wei, Stephen.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.
Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers by Paul J Neeson, Alexander James Davenport, Joseph A Trapani, Michael.
Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic.
How I treat refractory and early relapsed acute myeloid leukemia
Patient Tregs express normal levels of suppression.
Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia.
by Wolfgang Warsch, Christoph Walz, and Veronika Sexl
Cold agglutinin disease
Presentation transcript:

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones, Tracey Perry, Andrew Beggs, Elena Odintsova, Justin Loke, Guy Pratt, Kin Pong U, Anthony Lo, Margaret Ng, Pamela Kearns, Paul Cheng, and Carmela De Santo Blood Volume 125(15): April 9, 2015 ©2015 by American Society of Hematology

AML blasts are auxotrophic for arginine. Francis Mussai et al. Blood 2015;125: ©2015 by American Society of Hematology

BCT-100 arginine depletion reduces the number of viable AML blasts in vitro and in vivo. Francis Mussai et al. Blood 2015;125: ©2015 by American Society of Hematology

BCT-100 is cytotoxic against primary blasts from patients. Francis Mussai et al. Blood 2015;125: ©2015 by American Society of Hematology

BCT-100 depletes arginine intracellularly. Francis Mussai et al. Blood 2015;125: ©2015 by American Society of Hematology

BCT-100 halts proliferation and cell cycle arrest. Francis Mussai et al. Blood 2015;125: ©2015 by American Society of Hematology

BCT-100 induced cell cycle arrest leads to necrotic cell death. Francis Mussai et al. Blood 2015;125: ©2015 by American Society of Hematology